Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Hemophilia A
Hemophilia B
Спонсор: Pfizer
Налично на:
БГ
Обобщение
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Кой може да участва
Inclusion Criteria:
-Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.
Exclusion Criteria:
-None
Места на провеждане
4
Австралия (1)
Royal Prince Alfred Hospital
Camperdown , New South Wales
Taiwan (1)
National Taiwan University Hospital
Taipei
NOT_YET_RECRUITING
Турция (1)
Ege Universitesi Hastanesi
Izmir , İ̇zmir
САЩ (1)
The Regents of the University of California||UC Davis Health
БГ
EN